Friday, February 1, 2013
Arteriocyte Inc., of Cleveland, said it received FDA approval to start a Phase I trial testing its Magellan System technology in the treatment of thermal burn wounds.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.